Novel Dried Cryoprecipitate-Based Intervention to Improve Outcomes from Trauma and Hemorrhagic Shock: Applicability for Multidomain Operations
Abstract
Purpose of this study was to define the role of 5PRC and LPRC using 2 different small animal models of HS to examine the effect of these novel products on both hemostasis and endothelial protection. The long-term goal is FDA approval of these products for clinical and field use after HS. We HYPOTHESIZE that pathogen reduced cryoprecipitate-based interventions will decrease both early hemorrhagic deaths and later multiple organ failure (MOF) through their dual effects on hemostasis and endothelial stability. To test this hypothesis, two specific aims were carried out: SA1. Determine the effect of early cryoprecipitate on hemostasis, organ function,and mortality in a short- term mouse model of trauma and uncontrolled hemorrhage (UCH). SA2. Determine the effect of early cryoprecipitate on endothelial protection, MOF and mortality in a mouse model of sustained hypotensive resuscitation (SHR). Results from the current study have for the first time demonstrated in military relevant mouse models of hemorrhagic shock that cryoprecipitate has resuscitative and endothelial protective effects similar to that of plasma. Importantly, we have shown that immediate use cryoprecipitate is feasible and effective with newly developed pathogen-reduced long post thaw (five day) shelf-life cryoprecipitate (now FDA approved) and pathogen-reduced lyophilized cryoprecipitate, paving the way for their use in severely injured warfighters.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1216450
Entities
People
- Rosemary Kozar
Organizations
- University of Maryland, Baltimore